Sjöland H, Eitzman D T, Gordon D, Westrick R, Nabel E G, Ginsburg D
Division of Cardiology, Department of Internal Medicine, Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor 48109-0644, USA.
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):846-52. doi: 10.1161/01.atv.20.3.846.
Impaired fibrinolysis has been linked to atherosclerosis in a number of experimental and clinical studies. Plasminogen activator inhibitor type 1 (PAI-1) is the primary inhibitor of plasminogen activation and has been proposed to promote atherosclerosis by facilitating fibrin deposition within developing lesions. We examined the contribution of PAI-1 to disease progression in 2 established mouse models of atherosclerosis. Mice lacking apolipoprotein E (apoE-/-) and mice lacking the low density lipoprotein receptor (LDLR-/-) were crossbred with transgenic mice overexpressing PAI-1 (resulting in PAI-1 Tg(+)/apoE-/- and PAI-1 Tg(+)/LDLR-/-, respectively) or were crossbred with mice completely deficient in PAI-1 gene expression (resulting in PAI-1-/-/apoE-/- and PAI-1-/-/LDLR-/-, respectively). All animals were placed on a western diet (21% fat and 0.15% cholesterol) at 4 weeks of age and analyzed for the extent of atherosclerosis after an additional 6, 15, or 30 weeks. Intimal and medial areas were determined by computer-assisted morphometric analysis of standardized microscopic sections from the base of the aorta. Atherosclerotic lesions were also characterized by histochemical analyses with the use of markers for smooth muscle cells, macrophages, and fibrin deposition. Typical atherosclerotic lesions were observed in all experimental animals, with greater severity at the later time points and generally more extensive lesions in apoE-/- than in comparable LDLR-/- mice. No significant differences in lesion size or histological appearance were observed among PAI-1-/-, PAI-1 Tg(+), or PAI-1 wild-type mice at any of the time points on either the apoE-/- or LDLR-/- genetic background. We conclude that genetic modification of PAI-1 expression does not significantly alter the progression of atherosclerosis in either of these well-established mouse models. These results suggest that fibrinolytic balance (as well as the potential contribution of PAI-1 to the regulation of cell migration) plays only a limited role in the pathogenesis of the simple atherosclerotic lesions observed in the mouse.
在多项实验和临床研究中,纤维蛋白溶解功能受损与动脉粥样硬化相关。纤溶酶原激活物抑制剂1(PAI-1)是纤溶酶原激活的主要抑制剂,有人提出它通过促进纤维蛋白在发展中的病变内沉积来促进动脉粥样硬化。我们在两种已建立的动脉粥样硬化小鼠模型中研究了PAI-1对疾病进展的影响。将缺乏载脂蛋白E的小鼠(apoE-/-)和缺乏低密度脂蛋白受体的小鼠(LDLR-/-)分别与过表达PAI-1的转基因小鼠杂交(分别产生PAI-1 Tg(+)/apoE-/-和PAI-1 Tg(+)/LDLR-/-),或者与完全缺乏PAI-1基因表达的小鼠杂交(分别产生PAI-1-/-/apoE-/-和PAI-1-/-/LDLR-/-)。所有动物在4周龄时开始给予西式饮食(21%脂肪和0.15%胆固醇),并在另外6、15或30周后分析动脉粥样硬化的程度。通过对主动脉基部标准化显微切片进行计算机辅助形态测量分析来确定内膜和中膜面积。还通过使用平滑肌细胞、巨噬细胞和纤维蛋白沉积标记物的组织化学分析来表征动脉粥样硬化病变。在所有实验动物中均观察到典型的动脉粥样硬化病变,在后期时间点病变更严重,并且在apoE-/-小鼠中病变通常比在可比的LDLR-/-小鼠中更广泛。在apoE-/-或LDLR-/-遗传背景下的任何时间点,PAI-1-/-、PAI-1 Tg(+)或PAI-1野生型小鼠之间在病变大小或组织学外观上均未观察到显著差异。我们得出结论,在这两种已建立的小鼠模型中,PAI-1表达的基因修饰均未显著改变动脉粥样硬化的进展。这些结果表明,纤维蛋白溶解平衡(以及PAI-1对细胞迁移调节的潜在作用)在小鼠中观察到的简单动脉粥样硬化病变的发病机制中仅起有限作用。